Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process TA
ID number 5108

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 November 2024 Awaiting development. Please note that following on from information provided to NICE by the company in March 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
07 November 2024 Awaiting development. Please note that following on from information provided to NICE by the company in March 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
15 March 2023 As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]. For information, the company have advised that they are no longer pursuing an extension to the existing Conditional Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
16 November 2022 Suspended. The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this appraisal at this time. Therefore, we are suspending the appraisal while we consider the next steps with the company.
14 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual